Trial Information

Summary: Prostate Cancer Study

The denosumab 20050147 study is a clinical trial that is investigating the effectiveness of the study drug, in possibly delaying the spread of cancer to your bones. The study will include about 1400 subjects in North America, South America, Europe, Australia, and New Zealand.

Men may be eligible to enroll in the denosumab 20050147 study if they have:

• Prostate cancer
• undergone a bilateral orchlectomy (removal of the testicles) or are being treated with hormone therapy
• a rising PSA (prostate specific antigen)
• not been taking oral disphosphonates for more than 3 months.

  All participants in the Denosumab 20050147 study will receive close medical supervision and ongoing assessments of their medical condition. This includes study related blood tests, bone scans, and x-rays at no cost. Study participants will also receive calcium and vitamin D supplements.

  Even if the Denosumab 20050147 study ends up providing you with no direct benefit, your participation may benefit others, including people with prostate cancer, by increasing our understanding of bone metastasis.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 5:45:45 AM